← Back to Clinical Trials
Recruiting NCT05474417

The Effects of the CF Carrier State on the Kidneys and Pancreas

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Carrier State
Sponsor Philip Polgreen
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,250
Sex ALL
Min Age 18 Years
Max Age 100 Years
Start Date 2021-12-20
Completion 2026-07

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.

Eligibility Criteria

CF Carrier Inclusion Criteria: * A CF Carrier identified via genetic testing Control Inclusion Criteria: * No previous CF carrier test results Exclusion Criteria: * CF patient status * Unable to speak English * Currently pregnant * Unable to provide written informed consent * Prisoner status * Currently taking any medications for the treatment of diabetes

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}